SCHEMBL6367227

SCHEMBL6367227

COc1cc(C)ccc1S(=O)(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCOLN3 Q8TDD5 1/20 0.55
MEP1B Q16820 1/20 0.54
ACHE P22303 1/20 0.52
ALPL P05186 2/20 0.48
KMT2A Q03164 4/20 0.47
USP2 O75604 1/20 0.47
GAA P10253 1/20 0.47
LMNA P02545 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MAPK1 P28482 2/20 0.45
PKM P14618 1/20 0.45
HTT P42858 1/20 0.45
TRPV4 Q9HBA0 1/20 0.44
POLB P06746 2/20 0.44
ALDH1A1 P00352 2/20 0.44
RECQL P46063 1/20 0.44
MAPT P10636 1/20 0.44
MEN1 O00255 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28325511 0.92 MCOLN3 (0.49) MCOLN3MEP1BACHEALPLKMT2A
SCHEMBL6278523 0.86 CA1 (0.44) MCOLN3MEP1BACHEALPLKMT2A
SCHEMBL1066283 0.85 KMT2A (0.60) ACHEKMT2AUSP2GAALMNA
Hydrochloric Acid SCHEMBL27809966 0.83 KMT2A (0.58) ACHEKMT2AUSP2GAALMNA
SCHEMBL12888826 0.82 MCOLN3 (0.57) MCOLN3MEP1BACHEALPLKMT2A
SCHEMBL7525321 0.81 MCOLN3 (0.39) MCOLN3MEP1BACHEALPLKMT2A
SCHEMBL51171 0.81 MCOLN3 (0.55) MCOLN3MEP1BACHEALPLKMT2A
SCHEMBL29469916 0.81 MCOLN3 (0.55) MCOLN3MEP1BACHEALPLKMT2A
SCHEMBL533956 0.81 TRPV4 (0.68) MCOLN3MEP1BACHEALPLKMT2A
SCHEMBL13290903 0.81 MCOLN3 (0.55) MCOLN3MEP1BACHEALPLKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014014472-A1 STARCH-BASED ADHESIVES EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2014-01-23 WO claimed
EP-4100001-B1 CONTROLLED RELEASE SYSTEM OF PHYTOCANNABINOIDS FORMULATIONS SOLUBLE IN AQUEOUS MEDIA, METHODS AND USES THEREOF I MED S COOP (ES) 2025-06-25 EP disclosed
CN-111302945-B Preparation method of 3-hydroxy-4-methoxy-2-nitrobenzoic acid 上海再启生物技术有限公司 2023-06-13 CN disclosed
US-20230081080-A1 CONTROLLED RELEASE SYSTEM OF PHYTOCANNABINOIDS FORMULATIONS SOLUBLE IN AQUEOUS MEDIA, METHODS AND USES THEREOF I+MED S. COOP. (ES) 2023-03-16 US disclosed
CN-115611877-A Sulfonamide compound, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2023-01-17 CN disclosed
EP-4100001-A1 CONTROLLED RELEASE SYSTEM OF PHYTOCANNABINOIDS FORMULATIONS SOLUBLE IN AQUEOUS MEDIA, METHODS AND USES THEREOF I+Med S. Coop. (ES) 2022-12-14 EP disclosed
EP-3359620-B1 METHOD OF MONITORING A PARAMETER OF A HYDROCARBON WELL, PIPELINE OR FORMATION JOHNSON MATTHEY PLC (GB) 2022-11-30 EP disclosed
WO-2021156291-A1 CONTROLLED RELEASE SYSTEM OF PHYTOCANNABINOIDS FORMULATIONS SOLUBLE IN AQUEOUS MEDIA, METHODS AND USES THEREOF I+MED S. COOP. (ES) 2021-08-12 WO disclosed
EP-3861996-A1 CONTROLLED RELEASE SYSTEM OF PHYTOCANNABINOIDS FORMULATIONS SOLUBLE IN AQUEOUS MEDIA, METHODS AND USES THEREOF I+Med S. Coop. (ES) 2021-08-11 EP disclosed
EP-3362448-B1 NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA INVENTIVA (FR) 2021-08-04 EP disclosed
CN-101087794-A Pharmaceutical compounds PIRAMED LTD (GB) 2007-12-12 CN disclosed
CN-1906163-A 4-phenylpiperidine derivatives as renin inhibitors NOVARTIS AG (CH) 2007-01-31 CN disclosed
CN-1867330-A N-substituted azacycles FMC CORP (US) 2006-11-22 CN disclosed
CN-1277824-C Piperazine derivatives HOFFMANN LA ROCHE (CH) 2006-10-04 CN disclosed
CN-1250549-C Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands HOFFMANN LA ROCHE (CH) 2006-04-12 CN disclosed
CN-1533382-A Piperazine derivatives - 2004-09-29 CN disclosed
CN-1522249-A Quinoline derivatives as ligands for neuropeptide Y receptors 2004-08-18 CN disclosed
CN-1483034-A Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands - 2004-03-17 CN disclosed
US-6211223-B1 BENZODIOXOL-5-YL-2-METHOXY-4-METHYLPHENYLSULFONYLAMINO-2-OXO ETHYL-1-METHYL-1HINDOLE-6-CARBOXYLIC ACID PFIZER INC. 2001-04-03 US disclosed
WO-1999020623-A1 INDOLE DERIVATIVE USEFUL AS ENDOTHELIN RECEPTOR ANTAGONIST PFIZER LIMITED (GB) 1999-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230081080-A1 CONTROLLED RELEASE SYSTEM OF PHYTOCANNABINOIDS FORMULATIONS SOLUBLE IN AQUEOUS MEDIA, METHODS AND USES THEREOF CNR2, CNR1, FAAH MCOLN3 543/4885MEP1B 4405/4885ACHE 791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.